GSK has posted first-half 2026 total revenue of GBP 16.0 billion (USD 21.5 billion), up 5% in constant currencies, with R&D spend of GBP 5.2 billion (USD 6.9 billion). Specialty medicines grew 14% to GBP 7.0 billion (USD 9.4 billion), led by HIV (GBP 3.9 billion, +10%, with Cabenuva +32% and Apretude +41%), oncology (GBP 1.1 billion, +22%, driven by Jemperli +33% and Blenrep more than doubling), and respiratory immunology (GBP 2.0 billion, +17%, on Nucala and Benlysta). Vaccines rose 6% to GBP 4.4 billion (USD 5.9 billion), with Shingrix at GBP 1.9 billion (+12%) and Arexvy +75%, whilst general medicines declined 7% on generic pressure for Trelegy and legacy inhalers.

Pipeline execution was active: bepirovirsen met Phase III endpoints in hepatitis B functional cure, efimosfermin gained breakthrough therapy designation (BTD) tags in MASH, and risvutatug rezetecan (in-licensed from China's Hansoh) became the first B7-H3 ADC with a Phase III overall survival win.

GSK will launch over 20 Phase III trials in 2026 under its Accelerate Growth cost programme targeting GBP 1.9 billion annual savings by 2029, and absorbed a GBP 1.3 billion impairment on camlipixant plus GBP 371 million on an Alector collaboration. The USD 10.6 billion Nuvalent acquisition adds zidesamtinib and neladalkib to the lung cancer portfolio.

Full-year guidance is 3% to 5% revenue growth and 7% to 9% core operating profit growth.